School Inner City Air Study (NCT05953233)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this randomized clinical trial is to test the efficacy of high efficiency particulate air (HEPA) cleaners in reducing respiratory viral exposure and infections in elementary school classrooms. Classrooms will be randomized to active vs. sham HEPA cleaners. The main questions it aims to answer are: * Do classroom HEPA cleaners reduce exposure to viruses? * Do classroom HEPA cleaners reduce student and teacher infections? * Do classroom HEPA cleaners reduce infections in family members?
Who can join: Review the eligibility criteria below.
Location: Mass General Brigham — Boston, Massachusetts
Age range: 6 Years to 90 Years
🧪 Interventions in This Study
- Active classroom HEPA cleaner (OTHER)
- Sham classroom HEPA cleaner (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Mass General Brigham — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 875-9878
Email: plai@mgh.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Viral Infection
- Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis — Washington D.C., District of Columbia
- Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) — San Francisco, California
- Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts — Washington D.C., District of Columbia
- Third Party Viral Specific T-cells (VSTs) — Akron, Ohio
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. — Houston, Texas
Explore by condition: All Viral Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.